The funding will help bring Progentec’s tool for identifying lupus flare ups and a biomarker-based disease-activity index closer to commercialization.
Technology Ventures News
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
Lead investor i2E, along with Chicago-based OCA Ventures and Rochester-based Mayo Clinic Ventures, funded in late November the first round of investment to assist Progentec Diagnostics in moving its predictive technology for the onset of lupus flares closer to commercialization.
Progentec Diagnostics, Inc. has completed first round financing of $1.25 million.